Novel Psychoactive Substance Testing

Novel Psychoactive Substance Testing

Aegis is pleased to offer industry-leading testing options to allow providers the opportunity to more completely understand an individual’s substance use pattern, and facilitate more informed care.

Novel psychoactive substances (NPS) are compounds designed to mimic the effects of prescription drugs, evade detection by typical drug testing methodologies, and avoid regulation. NPS can be described by numerous terms, including legal highs or research chemicals labelled ‘not for human use’.

  • NPS markets rapidly change in response to regulation from US and other international agencies.
  • NPS may potentiate drug interactions with prescription medications, leading to unintended overdoses.
  • Individuals are exposed to fentanyl, designer opioids and benzodiazepines knowingly, or unknowingly through counterfeit prescription drugs intended to mimic common drugs such as oxycodone, hydrocodone and alprazolam, among others.

Ordering Information
Aegis' NPS testing is available for urine or oral fluid specimens as an add-on by drug class. Providers may choose one or multiple classes based on medical necessity. 

Novel Psychoactive Substance Testing
The elements of our NPS test offerings are a testament to Aegis’ commitment to excellence and innovation. We continue to provide solutions that assist providers improve clinical care and prevent adverse outcomes. Current testing options include the following parent drugs and/or metabolites.

DESIGNER
OPIOIDS
  DESIGNER
BENZODIAZEPINES
  SYNTHETIC
STIMULANTS
  SYNTHETIC
CANNABINOIDS
1-Napthyl U-47700   Adinazolam   2-Fluoroamphetamine   4-CN-CUMYL-BUTINACA
2-Napthyl U-47700   Bromazolam   2-Fluoroethamphetamine   4F-ABUTINACA
2-Methyl AP-237   Clonazolam   2-Fluoromethamphetamine   4F-MDMB-BUTICA/4F-EMB-BUTICA
Acryl Fentanyl   Deschloroetizolam   2-Methylmethcathinone   4F-MDMB-BUTINACA
AP-238   Diclazepam   2-Methoxymethamphetamine   5Cl-AKB48
Benzyl Fentanyl   Etizolam   3-Fluorophenmetrazine   5F-AB-PFUPPYCA
Bromo Fentanyl   Flualprazolam   3/4-Fluoroamphetamine   5F-AMB
Brorphine   Flubromazepam   3/4-Fluoroethamphetamine   5F-BZO-POXIZID
Butonitazene   Flubromazolam   3/4-Fluoromethamphetamine   5F-CUMYL-PINACA
Chloro Fentanyl   Fluclotizolam   3/4-Methylmethcathinone   5F-EDMB-PICA
Cyclopropyl Fentanyl   Flunitrazolam   3,4-DMMA   5F-MDMB-PICA/5F-EMB-PICA
Desnitroisotonitazene   Meclonazepam   4F-3-methyl-alpha-PVP   5F-MDMB-PINACA
Despropionyl Fluorofentanyl   Metizolam   4-Fluoromethylphenidate   5F-AB-PINACA
Dipyanone   Phenazepam   Alpha-D2PV   5F-PB-22
Etazene       Alpha-PiHP   AB-CHMINACA 
Etonitazene  

HALLUCINOGENS/
DISSOCIATIVES

  Alpha-PHP   ADB-4en-PINACA
Flunitazene   2F-Deschloroketamine   Alpha-PVP   ADB-5Br-INACA
Fluoro Fentanyl   3Cl-PCP   5/6-APB   ADB-BINACA
Fluorofuranyl Fentanyl   3F-PCP   Benzylone   ADB-BUTINACA
Fluoroisobutyryl Fentanyl   3-OH-PCE   Butylone   ADB-FUBIATA
Isotonitazene   3-OH-PCP   Chloro-N,N-DMC   ADB-FUBICA
Methyl-THF-Fentanyl   3/4F-Deschloroketamine   Dimethylone   ADB-HEXINACA
Metodesnitazene   Deschloroketamine   Eutylone   ADB-PHETINACA
Metonitazene   Deschloro-N-Ethylketamine   Hydroxetamine   ADB-PINACA
N-piperidinyl Etonitazene   Fluorexetamine   MBZP   BZO-CHMOXIZID
N-pyrrolidino Etonitazene   Methoxy PCE   MDPHP   BZO-HEXOXIZID
Norcarfentanil   25E-NBOH   p-Methoxymethamphetamine   BZO-POXIZID
Protonitazene   Methoxy PCP   Methylenedioxy-PV8   CH-PIATA

4-Trifluoromethyl U-47700

      N-butyl Hexedrone   EMB-FUBINACA
U-49900       N-ethyl Heptedrone   FUB-AMB/MEP-FUBINACA
Valeryl Fentanyl       N-ethyl Hexedrone   FUB-PB-22
        N-ethyl Pentedrone   JWH-018
OTHER       NM N-cyclohexyl Methylone   JWH-073
Phenibut       N,N-dimethyl Pentylone   MDMB-4en-PINACA
Tianeptine       Pentylone   MDMB-5Br-INACA
Xylazine       TFMPP    MMB-4en-PICA
            MMB-4en-PINACA
            MMB-FUBICA

 

A complete and up to date list of the analytes contained in each listed drug class can be found at: www.aegislabs.com/Paincompthresholds

*Parent drug listed for informational purposes only and not included in testing. Analytes listed for each drug class are current as of August 8, 2022. Updates and enhancements to the drug classes are made from time to time.


Recorded Webinars Available:



If you are a Healthcare Provider seeking information please contact your Regional Sales Manager or Client Services team at 1.800.533.7052 or email Client.Services@aegislabs.com